Search

Your search keyword '"Complement C3f"' showing total 4 results
Start Over Descriptor "Complement C3f" Publication Year Range Last 10 years
4 results on '"Complement C3f"'

1. A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification.

Author

Fania, Chiara, Sogno, Ilaria, Vasso, Michele, Torretta, Enrica, Leone, Roberta, Bruno, Antonino, Consonni, Paolo, Albini, Adriana, and Gelfi, Cecilia

Subjects
*PROSTATE-specific antigen, *ADENOCARCINOMA, *PROSTATE cancer, *MATRIX-assisted laser desorption-ionization, *PEPTIDES, *BIOMARKERS, *DIAGNOSIS
Abstract

Background Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods Samples from healthy controls and PCa patients with low (≤ 4 ng/mL) and high PSA (> 4 ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results MALDI profiling achieved to detect 10 and 14 changed peaks ( p -value < 0.05), respectively, in PCa patients with low and high PSA versus controls. In particular, a peak identified as C3f fragment, resulted overexpressed in low PSA PCa patients. Conclusions PSA test, coupled to MALDI profiling, is able to detect changes, specifically related to PCa, in low molecular weight protein range. Furthermore, for the first time in prostate cancer research, the identification and quantification of the small peptide C3f appears to be relevant for the detection of false negatives, providing an additive diagnostic power to PSA ( p < 0.01) and suggesting its use in clinical tests. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

2. Profiling of schizophrenia-associated serum peptides by MALDI-TOF-MS

Author

Yaoyao Sun, Mingyuan Zhang, Yingli Fu, Na Zhou, Yaqin Yu, Yueying Wang, Xin Chen, Huiping Zhang, and Qiong Yu

Subjects
0301 basic medicine, Oncology, Adult, Male, Poor prognosis, medicine.medical_specialty, Proteome, Down-Regulation, Tandem mass spectrometry, Complement C3f, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Tandem Mass Spectrometry, Internal medicine, mental disorders, Medicine, Humans, Fibrinopeptide, Mechanisms of schizophrenia, Biological Psychiatry, Fibrinopeptide A, Training set, business.industry, Middle Aged, Up-Regulation, Psychiatry and Mental health, Matrix-assisted laser desorption/ionization, 030104 developmental biology, Neurology, Potential biomarkers, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Complement C3b, Schizophrenia, Female, Neurology (clinical), Neural Networks, Computer, business, Peptides, 030217 neurology & neurosurgery, Algorithms, Biomarkers
Abstract

Schizophrenia is a psychiatric condition characterized by poor prognosis and severe symptoms that decrease the quality of life of patients. It is therefore important to develop rapid and reliable methods for early diagnosis. To achieve this aim, identification of accurate biomarkers will promote research into the mechanisms of schizophrenia and the design of effective diagnosis tools. Discriminative peptides in the serum of participants (277 schizophrenia patients and 294 healthy controls) were detected using the matrix-assisted laser desorption ionization time-of-flight tandem mass spectrometry (MALDI-TOF-MS). The diagnostic model for schizophrenia was validated using the ClinProTool software. Discrimination models were tested in the training set (200 schizophrenia patients and 200 healthy controls), and the robustness of the models was evaluated using the independent test set (77 cases and 94 controls). A total of 77 peaks were significantly different between schizophrenia patients and healthy controls with a signal-to-noise ratio of over 5. Among them, 35 peptides were down-regulated and 42 peptides were up-regulated in schizophrenia patients. With a cross-validation rate of 92.7% and a recognition capability rate of 96.5%, the supervised neural network comprising 25 discriminative peaks was found to be the most efficient model for schizophrenia diagnosis (sensitivity = 96.10%, specificity = 94.68%). Peptides at m/z = 2022.18 corresponded to complement C3f, and peptides at m/z = 1020.89, 1351.02, 1466.1 were identified as fragments of fibrinopeptide A. These two peptides may be potential biomarkers for schizophrenia in the Chinese population. The serum peptide levels present a potential clinical diagnostic tool for schizophrenia.

Published
2019

3. A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification

Author

Chiara Fania a, b, Ilaria Sogno c, Michele Vasso d, Enrica Torretta a, Roberta Leone a, Antonino Bruno c, Paolo Consonni c, Adriana Albini e, Cecilia Gelfi a, and f

Subjects
Complement C3f, Immunodepletion, MALDI profiling, Prostate cancer, Prostate-specific antigen, urologic and male genital diseases
Abstract

BACKGROUND: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. METHODS: Samples from healthy controls and PCa patients with low (4ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. RESULTS: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value

Published
2015
Full Text
View/download PDF

4. A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification

Author

Fania, C, Sogno, I, Vasso, M, Torretta, E, Leone, R, Bruno, A, Consonni, P, Albini, A, Gelfi, C, Chiara Fania, Ilaria Sogno, Michele Vasso, Enrica Torretta, Roberta Leone, Antonino Bruno, Paolo Consonni, Adriana Albini, Cecilia Gelfi, Fania, C, Sogno, I, Vasso, M, Torretta, E, Leone, R, Bruno, A, Consonni, P, Albini, A, Gelfi, C, Chiara Fania, Ilaria Sogno, Michele Vasso, Enrica Torretta, Roberta Leone, Antonino Bruno, Paolo Consonni, Adriana Albini, and Cecilia Gelfi

Abstract

Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value <. 0.05), respectively, in PCa patients with low and high PSA versus controls. In particular, a peak identified as C3f fragment, resulted overexpressed in low PSA PCa patients. Conclusions: PSA test, coupled to MALDI profiling, is able to detect changes, specifically related to PCa, in low molecular weight protein range. Furthermore, for the first time in prostate cancer research, the identification and quantification of the small peptide C3f appears to be relevant for the detection of false negatives, providing an additive diagnostic power to PSA (p<. 0.01) and suggesting its use in clinical tests.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results